BE2017C064I2 - - Google Patents

Download PDF

Info

Publication number
BE2017C064I2
BE2017C064I2 BE2017C064C BE2017C064C BE2017C064I2 BE 2017C064 I2 BE2017C064 I2 BE 2017C064I2 BE 2017C064 C BE2017C064 C BE 2017C064C BE 2017C064 C BE2017C064 C BE 2017C064C BE 2017C064 I2 BE2017C064 I2 BE 2017C064I2
Authority
BE
Belgium
Application number
BE2017C064C
Other languages
French (fr)
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04760321A external-priority patent/EP1617832B1/en
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of BE2017C064I2 publication Critical patent/BE2017C064I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE2017C064C 2003-04-29 2017-12-12 BE2017C064I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46683803P 2003-04-29 2003-04-29
EP04760321A EP1617832B1 (en) 2003-04-29 2004-04-21 Compositions for affecting weight loss
EP07116330A EP1870096A3 (en) 2003-04-29 2004-04-21 Compositions for affecting weight loss

Publications (1)

Publication Number Publication Date
BE2017C064I2 true BE2017C064I2 (en) 2023-08-09

Family

ID=38719840

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2017C064C BE2017C064I2 (en) 2003-04-29 2017-12-12

Country Status (6)

Country Link
EP (1) EP1870096A3 (en)
BE (1) BE2017C064I2 (en)
CY (2) CY1119418T1 (en)
FR (1) FR17C1058I2 (en)
LU (1) LUC00054I2 (en)
NL (1) NL300918I2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10576045B2 (en) 2011-02-16 2020-03-03 Nir Barak Low dosage combinations of fluoxetine and reboxetine for treating obesity
JP6406713B2 (en) 2013-01-30 2018-10-17 ファーモレックス セラピューティクス， インコーポレイテッド Treatment of depression and other diseases with low dose drugs

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217353A (en) * 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
AU3419995A (en) * 1994-09-19 1996-04-09 Du Pont Merck Pharmaceutical Company, The Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
DK0934069T3 (en) * 1996-05-07 2007-03-19 Pliva Istrazivanje I Razvoj D Method and apparatus for treating lipid and glucose metabolism disorders
EP1051167A1 (en) * 1998-01-29 2000-11-15 Sepracor, Inc. Pharmaceutical uses of optically pure (-) -bupropion
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
DK1326630T3 (en) * 2000-09-18 2008-09-15 Sanos Bioscience As Use of GLP-2 peptides
US20030087896A1 (en) * 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
BR0309969A (en) * 2002-05-17 2005-04-26 Merck Patent Gmbh Use of compounds that are effective as selective opioid receptor modulators
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake

Also Published As

Publication number Publication date
NL300918I2 (en) 2018-01-09
NL300918I1 (en) 2017-12-14
CY1119418T1 (en) 2018-03-07
LUC00054I2 (en) 2018-02-21
CY2017041I2 (en) 2018-09-05
FR17C1058I1 (en) 2018-01-12
EP1870096A3 (en) 2011-04-20
CY2017041I1 (en) 2018-09-05
LUC00054I1 (en) 2017-12-13
EP1870096A2 (en) 2007-12-26
FR17C1058I2 (en) 2019-01-11

Similar Documents

Publication Publication Date Title
BE2013C075I2 (en)
BE2013C069I2 (en)
BE2013C067I2 (en)
BE2013C038I2 (en)
BE2013C036I2 (en)
BE2011C030I2 (en)
JP2004081819A5 (en)
BE2013C034I2 (en)
BE2012C053I2 (en)
JP2004006278A5 (en)
JP2004196290A5 (en)
LUC00054I2 (en)
JP2003315808A5 (en)
JP2004046100A5 (en)
JP2003348625A5 (en)
AU2002348177A1 (en)
AU2002341905A1 (en)
AU2003207750A1 (en)
AU2002249912A1 (en)
AU2002245368A1 (en)
AU2002242943A1 (en)
AU2003210772A1 (en)
AU2003207787A1 (en)
AU2002362930A1 (en)
AU2002359010A1 (en)